Novotny Laura A, Clements John D, Goodman Steven D, Bakaletz Lauren O
Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's and The Ohio State University College of Medicine, Columbus, Ohio, USA.
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Clin Vaccine Immunol. 2017 Jun 5;24(6). doi: 10.1128/CVI.00563-16. Print 2017 Jun.
Otitis media (OM) is a common pediatric disease, and nontypeable (NTHI) is the predominant pathogen in chronic OM, recurrent OM, and OM associated with treatment failure. OM is also a polymicrobial disease, wherein an upper respiratory tract viral infection predisposes to ascension of NTHI from the nasopharynx, the site of colonization, to the normally sterile middle ear, resulting in disease. Using a clinically relevant viral-bacterial coinfection model of NTHI-induced OM, we performed transcutaneous immunization (TCI) via a band-aid delivery system to administer each of three promising NTHI vaccine candidates derived from bacterial adhesive proteins and biofilm mediators: recombinant soluble PilA (rsPilA), chimV4, and integration host factor. Each immunogen was admixed with the adjuvant LT(R192G/L211A), a double mutant of heat-labile enterotoxin, and assessed for relative ability to prevent the onset of experimental OM. For each cohort, the presence of circulating immunogen-specific antibody-secreting cells and serum antibody was confirmed prior to intranasal NTHI challenge. After bacterial challenge, blinded video otoscopy and tympanometry revealed a significant reduction in the proportion of animals with signs of OM compared to levels in animals receiving adjuvant only, with an overall vaccine efficacy of 64 to 77%. These data are the first to demonstrate the efficacy afforded by TCI with a band-aid vaccine delivery system in a clinically relevant polymicrobial model of OM. The simplicity of TCI with a band-aid and the significant efficacy observed here hold great promise for reducing the global burden of OM in the pediatric population.
中耳炎(OM)是一种常见的儿科疾病,不可分型流感嗜血杆菌(NTHI)是慢性中耳炎、复发性中耳炎以及与治疗失败相关的中耳炎的主要病原体。中耳炎也是一种多微生物疾病,其中上呼吸道病毒感染易使NTHI从定植部位鼻咽部上升至正常无菌的中耳,从而引发疾病。我们使用NTHI诱导的中耳炎的临床相关病毒 - 细菌共感染模型,通过创可贴给药系统进行经皮免疫(TCI),以施用三种有前景的源自细菌粘附蛋白和生物膜介质的NTHI疫苗候选物:重组可溶性菌毛蛋白A(rsPilA)、嵌合体V4和整合宿主因子。每种免疫原均与佐剂LT(R192G/L211A)混合,LT(R192G/L211A)是一种不耐热肠毒素的双突变体,并评估其预防实验性中耳炎发作的相对能力。对于每个队列,在鼻内接种NTHI之前确认循环免疫原特异性抗体分泌细胞和血清抗体的存在。细菌攻击后,盲法视频耳镜检查和鼓室图显示,与仅接受佐剂的动物相比,出现中耳炎体征的动物比例显著降低,总体疫苗效力为64%至77%。这些数据首次证明了在临床相关的中耳炎多微生物模型中,创可贴疫苗给药系统经皮免疫的疗效。创可贴经皮免疫的简便性以及此处观察到的显著疗效对于减轻儿科人群中耳炎的全球负担具有巨大潜力。